Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    dreamm 3

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04246047
Recruitment Status : Recruiting
First Posted : January 29, 2020
Last Update Posted : December 10, 2020
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 21, 2023
Estimated Study Completion Date : August 13, 2026